Feb 162026 A first-in-class small-molecule inhibitor targeting AVIL exhibits safety and antitumor efficacy in preclinical models of glioblastoma Sci. Transl. Med. 18, eadt1211 (2026). DOI:10.1126/scitranslmed.adt1211 Select the format you want to export the citation of this publication.
